Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stake Reduced by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. lessened its holdings in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,584 shares of the company’s stock after selling 10,079 shares during the period. Stratos Wealth Partners LTD. owned 0.88% of Global X Genomics & Biotechnology ETF worth $598,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GNOM. Oxinas Partners Wealth Management LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at $103,000. Atria Investments Inc bought a new stake in Global X Genomics & Biotechnology ETF in the third quarter worth about $122,000. Centaurus Financial Inc. raised its position in Global X Genomics & Biotechnology ETF by 7.0% in the third quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock worth $169,000 after acquiring an additional 985 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in Global X Genomics & Biotechnology ETF in the 3rd quarter valued at about $205,000. Finally, James J. Burns & Company LLC boosted its position in shares of Global X Genomics & Biotechnology ETF by 6.0% during the 3rd quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after purchasing an additional 1,038 shares in the last quarter. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM opened at $9.46 on Wednesday. The stock has a market capitalization of $65.94 million, a P/E ratio of -4.04 and a beta of 1.03. The firm’s 50 day moving average is $10.05 and its 200-day moving average is $10.62. Global X Genomics & Biotechnology ETF has a 12-month low of $9.41 and a 12-month high of $12.53.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.